Dapagliflozin (propanediol monohydrate) (Forxiga) is now indicated in adults for the treatment of symptomatic heart failure independent of left ventricular ejection fraction, as an adjunct to standard of care therapy.
Dupilumab (Dupixent) is now indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy.
Ferric carboxymaltose (Ferinject) is now indicated for treatment of iron deficiency anaemia in children aged 1 to 13 years when oral iron preparations are ineffective or cannot be used.
Finerenone (Kerendia) is now indicated to reduce the risk of cardiovascular mortality and morbidity in adults with chronic kidney disease (with albuminuria) associated with Type 2 diabetes, in addition to standard of care.
Influenza virus vaccine, surface antigen, quadrivalent (inactivated) (Flucelvax Quad) is now indicated for use in children from 6 months of age and older for the prevention of influenza caused by influenza virus types A and B contained in the vaccine.
Upadacitinib (Rinvoq)is now indicated for the treatment of adult patients with moderately to severely active Crohn’s disease, who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biological medicine.
Sacituzumab govitecan (Trodelvy) is now indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy (including a CDK4/6 inhibitor) and at least two additional systemic therapies in the locally advanced or metastatic setting.
New Contraindications
Ravulizumab (Ultomiris 100 mg/mL) is now contraindicated in patients who are not currently vaccinated against Neisseria meningitidis, unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination.
This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.
To contact MIMS editorial please email editorial@mims.com.au. To enquire about purchasing a product please contact MIMS Customer service on 1800 800 629 or email subscriptions@mims.com.au. For more information about MIMS, please see www.mims.com.au.
